Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR

a Radiology, Johns Hopkins University, Baltimore, MD, USA b Psychiatry, Johns Hopkins University, Baltimore, MD, USA c Neuroscience, Johns Hopkins University, Baltimore, MD, USA d Clinical and Exploratory Pharmacology, Sanofi-aventis Research and Development, Bridgewater, NJ, USA e Clinical and Exploratory Pharmacology, Sanofi-aventis Research and Development, Malvern, PA, USA f Clinical and Exploratory Pharmacology, Sanofi-aventis Research and Development, Paris, France